CAPRANICO, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 5.868
EU - Europa 5.793
AS - Asia 5.625
AF - Africa 370
SA - Sud America 254
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 9
Totale 17.931
Nazione #
US - Stati Uniti d'America 5.773
IT - Italia 2.183
CN - Cina 1.704
SG - Singapore 1.644
GB - Regno Unito 982
VN - Vietnam 974
DE - Germania 542
SE - Svezia 422
FR - Francia 362
HK - Hong Kong 356
UA - Ucraina 295
IN - India 286
RU - Federazione Russa 209
IE - Irlanda 178
KR - Corea 161
BR - Brasile 160
CI - Costa d'Avorio 140
JP - Giappone 120
NL - Olanda 107
FI - Finlandia 105
CH - Svizzera 100
ZA - Sudafrica 95
BD - Bangladesh 68
EE - Estonia 60
CA - Canada 55
JO - Giordania 53
PK - Pakistan 50
TG - Togo 50
SC - Seychelles 47
AR - Argentina 39
BG - Bulgaria 37
AT - Austria 31
PL - Polonia 31
BE - Belgio 29
TR - Turchia 29
PH - Filippine 28
MX - Messico 26
DK - Danimarca 24
ID - Indonesia 24
TH - Thailandia 23
GR - Grecia 21
ES - Italia 19
HR - Croazia 19
TW - Taiwan 19
IQ - Iraq 14
CZ - Repubblica Ceca 13
EC - Ecuador 13
IR - Iran 11
AU - Australia 9
SY - Repubblica araba siriana 9
BO - Bolivia 8
CL - Cile 8
EU - Europa 8
RO - Romania 8
UZ - Uzbekistan 8
MY - Malesia 7
SA - Arabia Saudita 7
TN - Tunisia 7
VE - Venezuela 7
ZW - Zimbabwe 7
EG - Egitto 6
IL - Israele 6
PE - Perù 6
PY - Paraguay 6
CO - Colombia 5
LB - Libano 5
AE - Emirati Arabi Uniti 4
BY - Bielorussia 4
JM - Giamaica 4
NG - Nigeria 4
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
NZ - Nuova Zelanda 3
OM - Oman 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
AZ - Azerbaigian 2
CR - Costa Rica 2
DZ - Algeria 2
ET - Etiopia 2
LT - Lituania 2
MU - Mauritius 2
SN - Senegal 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
BS - Bahamas 1
BZ - Belize 1
CV - Capo Verde 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GP - Guadalupe 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
Totale 17.926
Città #
Singapore 1.198
Southend 807
Bologna 560
Ashburn 510
Chandler 456
Hefei 422
Santa Clara 417
Fairfield 386
San Jose 342
Hong Kong 286
Ann Arbor 247
Woodbridge 242
Cambridge 209
Ho Chi Minh City 198
Jacksonville 196
Wilmington 192
Seattle 191
Princeton 189
Milan 186
Hanoi 181
Houston 178
Dublin 177
Dong Ket 149
Seoul 147
Abidjan 140
Beijing 128
Boardman 128
Naples 118
Dallas 115
Tokyo 114
Helsinki 90
Lauterbourg 90
Nanjing 89
Rome 88
Westminster 83
Council Bluffs 82
Los Angeles 75
Padova 75
Bern 71
Berlin 59
New York 59
Jinan 58
Buffalo 54
Amman 52
Hyderabad 51
Lomé 50
Shenyang 46
Guangzhou 44
Medford 42
Munich 41
Da Nang 40
Mülheim 39
Shanghai 39
Frankfurt am Main 37
Sofia 37
Saint Petersburg 36
Changsha 35
Bengaluru 34
Florence 34
Hebei 30
Haiphong 29
Verona 29
Falkenstein 28
Nanchang 28
Redondo Beach 28
Brussels 27
Mahé 25
San Diego 25
Zhengzhou 23
Phoenix 22
Redmond 22
São Paulo 21
Vienna 21
Des Moines 20
Mardan 20
Tianjin 20
Wuhan 20
Reggio Emilia 19
Rimini 19
Fremont 18
Modena 18
Montreal 18
Redwood City 18
Hangzhou 17
Jakarta 17
Jiaxing 17
Chicago 16
Lanzhou 16
Johannesburg 15
The Dalles 15
Turin 15
Warsaw 15
Dearborn 14
Fuzhou 14
Hải Dương 14
Ningbo 14
Paris 14
Biên Hòa 13
Falls Church 13
Ferrara 13
Totale 11.239
Nome #
Biotecnologie e modificazioni genetiche. Scienza, etica, diritto 646
Biologia molecolare. Con ebook. Con software di simulazione 534
Mechanistic roles of R-loops and micronuclei in the innate immune response induced by anticancer G-quadruplex binders 380
G-quadruplex–R-loop interactions and the mechanism of anticancer G-quadruplex binders 372
Balancing Affinity, Selectivity, and Cytotoxicity of Hydrazone-Based G-Quadruplex Ligands for Activation of Interferon β Genes in Cancer Cells 291
G-quadruplex binders as cytostatic modulators of innate immune genes in cancer cells 289
R loop-driven genome instability by G-quadruplex binders in BRCA2-silenced human cancer cells. 285
DNA damage and genome instability by G-quadruplex ligands are mediated by R loops in human cancer cells 265
Human DNA topoisomerase I poisoning causes R loop-mediated genome instability attenuated by transcription factor IIS 256
G-quadruplex binders cause DNA damage by inducing R loops in human cancer cells. 256
Enhanced CPT sensitivity of yeast cells and selective relaxation of Gal4 motif-containing DNA by novel Gal4-Topoisomerase I fusion proteins. 245
Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway 240
Novel DNA Topoisomerase IIα Inhibitors from Combined Ligand- and Structure-Based Virtual Screening 238
Toward the Development of Specific G‑Quadruplex Binders: Synthesis, Biophysical, and Biological Studies of New Hydrazone Derivatives 231
Characterization of novel antisense HIF-1α transcripts in human cancers 229
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives 228
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF SUSTITUTED NAPHTHALENE IMIDES AND DIIMIDES AS ANTICANCER AGENT 224
DNA Topoisomerase I differentially modulates R-loops across the human genome 218
Monohydrazone Based G-Quadruplex Selective Ligands Induce DNA Damage and Genome Instability in Human Cancer Cells 215
A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors. 214
MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells 213
Ligands stimulating antitumour immunity as the next G-quadruplex challenge 209
Interaction model for anthracycline activity against DNA topoisomerase II. 201
Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells. 195
Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks 195
Antisense transcripts enhanced by camptothecin at divergent CpG-island promoters associated with bursts of topoisomerase I-DNA cleavage complex and R-loop formation 194
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 189
Genome instability by G-quadruplex ligands are mediated by R-loops in human cancer cells 189
Non-canonical activating roles of RCoR2 sustain transcription in adrenergic neuroblastoma 188
Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: Implications for physiological and therapeutic modulation of enzyme activity. 187
RNA G-Quadruplexes in Kirsten Ras (KRAS) Oncogene as Targets for Small Molecules Inhibiting Translation 178
Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell lung cancer: a feasible strategy? 177
Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II 177
Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene. 177
Non-B DNA structures as a booster of genome instability 175
The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I. 175
G1 Cell-Cycle Arrest and Apoptosis by Histone Deacetylase Inhibition in MLL-AF9 Acute Myeloid Leukemia Cells Is MLL-AF9 Independent 175
Novel symmetric and asymmetric DNA scission determinants for streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site. 173
Chromatin binding sites of DNA topoisomerase I, RNA polymerase II and TBP in transcribed genes in human cancer cells 173
Correlation between neuronal differentiation and beta catenin distribution in medulloblastoma 172
Intracellular beta-catenin relocalization after APC gene silencing by si-RNA in human madulloblastoma cell lines 171
Development of DNA topoisomerase-related therapeutics. A short perspective of new challenges. 170
DNA topoisomerase I as a transcription protein and a lethal cellular toxin. 169
A long antisense RNA is transcribed at the 5’ end of the human HIF-1a gene upon drug inhibition of DNA Topoisomerase I. 169
Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation. 167
Mapping and dynamics of DNA topoisomerase I recruitment at a transcribed human gene locus 165
Targeting human telomeric and promoter G-quardruplexes: synthesis, biophysical and biological studies of new guanylhydrazones as potential antitumor agents 163
Effects of common buffer systems on drug activity: the case of clerocidin. 162
Mapping DNA topoisomerase I, RNA polymerase II and other proteins at a human gene locus during transcription inhibition 162
Electron Paramagnetic Resonance (EPR) Study of Spin-Labeled Camptothecin Derivatives: A Different Look of the Ternary Complex. 161
Sistema Wnt e differenziamento in linee cellulari di medulloblastoma 156
Global transcription regulation by DNA topoisomerase I in exponentially growing Saccharomyces cerevisiae cells: Activation of telomere-proximal genes by TOP1 deletion 156
Transcriptional Stress by Camptothecin: Mechanisms and Implications for the Drug Antitumor Activity 153
DROPA: DRIP-seq optimized peak annotator 153
TDP1 mutation causing SCAN1 neurodegenerative syndrome hampers the repair of transcriptional DNA double-strand breaks 152
DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1a gene locus. 151
Mapping and dynamics of DNA topoisomerase I recruitment at a transcribed human gene locus 150
Immunofluorescence microscopy of G-quadruplexes and R-loops 149
Intracellular distribution of beta-catenin in human medulloblastoma cell lines with different degree of neuronal differentiation 149
Rapid and specific disassembly of RNA polymerase II from transcribed chromatin regions after topoisomerase I poison treatments of human cancer cells 148
G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent 148
Expression of down-regulated ERV LTR elements associates with immune activation in human small-cell lung cancers 146
Toward the development of specific G-quadruplex binders: biophysical studies of new hydrazone derivatives. 146
DNA topoisomerasi I e sviluppo di nuovi inibitori. 144
Gene expression signature of aneuploidy in acute myeloid leukemia 144
Wnt system and differentiation in medulloblastoma cell lines 142
Cellular response to camptothecin at transcribing chromatin 141
Camptothecin effects on transcription-related events. 140
Biologia molecolare 140
Synthesis and Evaluation of New Naphthalene and Naphthoquinone Derivatives as Anticancer Agents 139
Antitumor AZA-anthrapyrazoles: biophysical and biochemical sudies on 8-aza and 9-aza regioisomers. 139
Current Pharmaceutical Design 138
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation. 136
The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 alpha Activity by Changing miR Expression Patterns in Human Cancer Cells 135
Mapping DNA breaks by next-generation sequencing 133
Topoisomerase I specifically affects RNA polymerase II paused at promoter-proximal sites in human cells. 132
Discovery of new antisense transcripts induced by camptothecin at CpG island promoters of human cells. 132
A rational selection of drug targets needs deeper insights into general regulation mechanisms. 132
DNA topoisomerase I (Top1) can regulate the coupling of RNA polymerase II (RNAP) pausing at promoter-proximal sites and transcript maturation in human cells. 131
Dynamics of RNA polymerase II recruitment to active gene promoters following topoisomerase I (Top1)-mediated DNA damage in S. cerevisiae 131
Naphthoquinone Derivatives Exert Their Antitrypanosomal Activity via a Multi-Target Mechanism 130
Metallothionein cDNA cloning, metallothionein expression and haevy metals in Scapharca inaequivalvis along the Northern Adriatic coast of Italy 130
Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors. 129
Discovery of the first dual G-triplex/G-quadruplex stabilizing compound: A new opportunity in the targeting of G-rich DNA structures? 129
Correlation between neuronal differentiation and beta catenin distribution in medulloblastoma 128
Novel Ametantrone-Amsacrine Related Hybrids as Topoisomerase IIβ Poisons and Cytotoxic Agents 128
Induction of a novel long antisense RNA from the human HIF-1a locus may contribuite to HIF 1a regulation and inhibition by campotecin in cancer cells. 127
Significant effects of DNA topoisomerase I on global gene expression profiles in S. cerevisiae 127
Anti-Cancer Agents in Medicinal Chemistry 126
DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions 126
Global gene expression analyses after camptothecin treatments of yeast cells 125
Dynamic effects of topoisomerase i inhibition on R-loops and short transcripts at active promoters 123
Transcriptional Topoisomerase I functions: implications for tumor resistance to enzyme poisons. 118
Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin 116
Metallothionein cDNA cloning and RT-PCR inhibitors in Scapharca inaequivalvis 115
null 108
Genomic context influences translesion synthesis DNA polymerase-dependent mechanisms of micronuclei induction by G-quadruplexes 102
Target specificity of effective anticancer therapeutics 97
Highly Purified Top1-Bound DNA Fragments 91
Type I DNA Topoisomerases 89
Totale 17.877
Categoria #
all - tutte 46.178
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.178


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021275 0 0 0 0 0 0 0 0 0 0 0 275
2021/20221.792 149 53 138 177 171 131 42 153 86 79 319 294
2022/20232.227 202 288 106 260 131 158 92 241 403 46 134 166
2023/2024815 49 101 40 63 91 106 51 46 50 39 117 62
2024/20252.946 138 349 264 190 572 141 248 130 64 160 183 507
2025/20266.144 429 659 612 555 741 369 611 236 941 433 326 232
Totale 18.183